Groowe Groowe / Newsroom / IONS
⏱ News is delayed by 15 minutes. Sign in for real-time access. Sign in

IONS News

Ionis Pharmaceuticals, Inc. Common Stock

IONS SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving Ionis Pharmaceuticals

prnewswire.com
IONS

Form 8-K

sec.gov
IONS

Ionis Pharmaceuticals Investigation Notice: Levi & Korsinsky Notifies Investors of a Pending Investigation Into Ionis Pharmaceuticals (IONS)

prnewswire.com
IONS

Form 8-K

sec.gov
IONS

Update on CARDIO-TTRansform Phase 3 trial of eplontersen in adults with transthyretin-mediated amyloid cardiomyopathy

businesswire.com
IONS

Transthyretin Amyloidosis Treatment Market Size to Reach USD 35.10 Billion by 2035, Growing at a 14.64% CAGR | SNS Insider

globenewswire.com
ALNY BIIB PFE IONS

Ionis completes enrollment in pivotal cohort of the Phase 3 REVEAL study evaluating obudanersen in Angelman syndrome

businesswire.com
IONS

IgA Nephropathy Clinical Trial Space Intensifies with 25+ Companies in Active Development | DelveInsight

globenewswire.com
NVS VRTX BIIB VTRS AZN IONS TAK ARWR BHVN NVO LLY LXRX XRTX REGN FMS MDT AMPH DRCT BMRC MAZE

Ionis announces license agreement with Recordati for zilganersen in Alexander disease (AxD) in all countries outside the U.S.

businesswire.com
IONS

Form 8-K

sec.gov
IONS